AUTHORS
Emilie Audouard, Fanny Michel, Vanessa Pierroz, Taeuk Kim, Lisa Rousselot, Béatrix Gillet-Legrand, Gaëlle Dufayet-Chauffaut, Peter Buchmann, Michael Florea, Alexander Khel, Kamilya Altynbekova, Claudia Delgaldo, Encarna Escudero, Alejandra Ben Aissa Soler, Nathalie Cartier, Francoise Piguet, Marc Folcher
J Control Release. 2022 Dec;352:994-1008. doi: 10.1016/j.jconrel.2022.11.008. Epub 2022 Nov 16.
ABSTRACT
Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for optogenetic controlled interferon-β delivery (Optoferon cells) in a bioelectronic cell-based implant. Optoferon cells transcriptomic profiling was used to elaborate an in-silico model of the recombinant interferon-β production. Wireless optoelectronic device integration was developed using additive manufacturing and injection molding. Implant cell-based optoelectronic interface manufacturing was established to integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic cell-based implant biocompatibility, and device performances were evaluated in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model of multiple sclerosis.
PMID:36370877 | PMC:PMC9733677 | DOI:10.1016/j.jconrel.2022.11.008
